Effectiveness and Safety of the Low-Molecular-Weight Heparin CY 216 in the Prevention of Fatal Pulmonary Embolism and Thromboembolic Death in General Surgery

Pezzuoli, G; Serneri, Gian Gastone Neri; Settembrini, Piergiorgio; Coggi, Guido; Olivari, N.; Negri, Giampiero; Codemo, R; Galli, G.; Roveri, Sergio

doi:10.1159/000216178

Cited by 7 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical trials have shown that LMW heparins are effective in preventing DVT following general (13)(14)(15) and orthopedic surgery (16)(17)(18) and in reducing post-operative mortality (19). Reports on the use of these agents for the treatment of established DVT are less numerous (20)(21)(22)(23)(24)(25).…”

Section: Introductionmentioning

confidence: 99%

Subcutaneous Low Molecular Weight Heparin versus Subcutaneous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis: a Polish Multicenter Trial

Łopaciuk

Filipecki³

et al. 1992

Thromb Haemost

153

View full text Add to dashboard Cite

SummaryIn a prospective multicenter trial, 149 consecutive patients with phlebographically proven proximal and/or distal deep vein thrombosis of the leg were randomly allocated to receive subcutaneously for 10 days either low molecular weight heparin CY 216 (Fraxiparine) in a fixed dose or unfractionated heparin (UFH) in doses adjusted according to the activated partial thromboplastin time. Pre- and post-treatment phlebograms were assessed blindly using the Arnesen’s score system in 134 patients available for analysis of the treatment efficacy. The mean phlebographic score after 10 days of treatment was significantly decreased in both groups (p <0.001) in comparison with the baseline score but the difference in score changes between the two groups was not statistically significant. There was an improvement in 45/ 68 patients (66%) in the Fraxiparine group and in 32/66 patients (48%) in the UFH group, and an increase in the thrombus size in 10/68 (15%) and 12/66 (18%), respectively. One symptomatic non-fatal pulmonary embolism and one major bleeding episode were observed in the UFH group. During a follow-up period of 3 months, two rethromboses had occurred in the UFH group and none in the Fraxiparine group. It is concluded that subcutaneous fixed dose Fraxiparine is safe and at least as effective as subcutaneous adjusted UFH in the treatment of deep vein thrombosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Subcutaneous Low Molecular Weight Heparin versus Subcutaneous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis: a Polish Multicenter Trial

Łopaciuk

Filipecki³

et al. 1992

Thromb Haemost

153

View full text Add to dashboard Cite

show abstract

“…Mientras que la introducción de tromboprofilaxis farmacológica, si ha modificado la incidencia de ETE en los pacientes quirúrgicos (18,19), no parece que el efecto haya sido similar en los pacientes "médicos" (20). Así en las series recientes de autopsia donde se objetivó tromboembolismo pulmonar, solo una cuarta parte de los pacientes tenían antecedentes quirúrgicos, dato que se mantiene también en nuestro estudio (22,5%).…”

Section: Discussionunclassified

Tromboembolismo pulmonar en pacientes hospitalizados entre 1994-2000: serie de autopsia

Fernández

Holguín

García

et al. 2006

An. Med. Interna (Madrid)

View full text Add to dashboard Cite

RESUMENIntroducción: El tromboembolismo pulmonar (TEP) ha sido durante muchos años una causa muy importante de morbi-mortalidad en los pacientes hospitalizados. El empleo de forma profiláctica de Heparinas de Bajo Peso Molecular (HBPM) en pacientes ingresados en la última década del siglo XX parece haber disminuido de forma significativa su incidencia clí-nica. Pretendemos ver si el empleo de HBPM como medida de tromboprofilaxis ha modificado el hallazgo de esta patología en autopsias.Material y métodos: Estudio retrospectivo de todas las autopsias realizadas en adultos en el Hospital Clínico San Carlos (Madrid) en un periodo de 6 años (Enero 1994-Diciembre 1999. Se incluyeron en el estudio todas aquellas que presentaron hallazgos anatomopatológicos (AP) de TEP y se rellenó un protocolo en el que se incluyeron datos AP, datos epidemiológicos, clínicos y terapéuticos.Resultados: En el periodo estudiado se realizaron 483 necropsias, de las cuales 40 (8,3%) tenían datos de TEP. La mayor parte de ellos tenían más de 50 años (85%) y entre los factores de riesgo destacaron el reposoencamamiento, la enfermedad crónica médica y la presencia de tumores malignos (adenocarcinomas). Sólo se sospechó el diagnóstico pre-mortem en 5 (12,5 %) y 15 (37,5 %) desarrollaron la ETE a pesar de haber recibido tratamiento profiláctico con HBPM.Conclusiones: El TEP continúa siendo una causa muy importante de mortalidad de los pacientes ingresados en el hospital. El aumento de la esperanza de vida, de la supervivencia de enfermedades crónicas médicas y tumorales determina que hay que tener muy en cuenta esta patología. El empleo de una HBPM como profilaxis no excluye la posibilidad de esta entidad.PALABRAS CLAVE: Autopsia. Tromboembolismo pulmonar. HBPM. ABSTRACT Background: Pulmonary thromboembolism (PTE) has been for a long time a significant cause of morbidity and mortality in hospitalized patients. The utility of Low-Molecular Weight Heparins (LMWH) in these patients in the last decade of the XX century has decreased the incidence of this disease. We try to know if the massive useful of LMWH as thromboprophylasis is diminishing its incidence in autopsies.Material

show abstract

“…Can the Multicentre Trial (MCT) 15 trial of 1975 and the Step Study Group (STEP) 16 trial of 1990 be compared? The fact that there were four times more fatal PEs in the untreated control group in the earlier trial for unknown reasons (16 of 2045 and 4 of 2247, respectively) makes one suspicious of a difference between either the designs of the two trials or a difference in clinical or technical skills over time.…”

Section: Time Between Trialsmentioning

confidence: 99%

“…In addition, the use of LMWH seems to reduce the incidence of nonfatal PEs (Table 5). In Table 5, the calculation for the placebo group was not carried out because approximately 90% of the patients of this group are from the STEP study 16 in which the endpoint was the prevention of fatal PE and thus the nonfatal PEs were not reported.…”

Section: Table 3 Record Of the Reported Pes Regardless Of Type And Qmentioning

confidence: 99%

Is Pulmonary Embolism a Suitable Evaluation Criterion of the Efficacy of Prophylactic Treatment in Surgery?

Toulemonde¹,

Doutremépuich²

1991

Semin Thromb Hemost

View full text Add to dashboard Cite

Effectiveness and Safety of the Low-Molecular-Weight Heparin CY 216 in the Prevention of Fatal Pulmonary Embolism and Thromboembolic Death in General Surgery

Cited by 7 publications

References 7 publications

Subcutaneous Low Molecular Weight Heparin versus Subcutaneous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis: a Polish Multicenter Trial

Subcutaneous Low Molecular Weight Heparin versus Subcutaneous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis: a Polish Multicenter Trial

Tromboembolismo pulmonar en pacientes hospitalizados entre 1994-2000: serie de autopsia

Is Pulmonary Embolism a Suitable Evaluation Criterion of the Efficacy of Prophylactic Treatment in Surgery?

Contact Info

Product

Resources

About